<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335628</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the Effect of mRNA and Inactivated SARS-CoV-2 Vaccines on the Levels of Cytokines IL-2, IFN-γ, and Anti-RBD Spike SARS-CoV-2 Antibodies in People Living with HIV (PLHIV).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2115</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines12092115</ELocationID><Abstract><AbstractText>The safety of the mRNA and inactivated SARS-CoV-2 vaccine has been demonstrated for people living with HIV (PLHIV). However, vaccine studies in PLHIV are limited, and there is a gap in which vaccine type provides the best response in PLHIV. Thus, PLHIV may benefit from mRNA vaccine types compared to inactivated vaccines. This study aims to assess the immune responses to vaccination by measuring specific antibodies (IgG) targeting the receptor binding sites (RBDs) of the SARS-CoV-2 virus and the levels of IL-2 and IFN-γ in plasma. A total of 41 PLHIV who regularly take antiretroviral therapy (ART) over a period of six months, along with 31 individuals in a healthy control group (HC), were administered either two mRNA or inactivated vaccines. Data regarding demographics and clinical information were gathered from the medical records. An analysis was conducted on the neutralisation antibody IgG specific to RBD using the chemiluminescence microparticle assay (CMIA). The levels of IL-2 and IFN-γ were quantified using the Luminex assay method from plasma samples. Data were collected in the laboratory 28 days after each vaccination. After the first vaccination, the level of anti-SARS-CoV-2 RBD IgG was higher in PLHIV who received the mRNA vaccines than those who received inactivated vaccines (<i>p</i> = 0.006). The levels of mRNA in the PLHIV group showed a significant correlation with IL-2 and IFN-γ after the second vaccination (<i>r</i> = 0.51, <i>p</i> = 0.0035; <i>r</i> = 0.68, <i>p</i> = 0.002). The group of PLHIV who received the inactivated vaccine showed increased IL-2 and IFN-γ after the initial vaccination, compared to PLHIV who received the mRNA vaccine (<i>p</i> = 0.04; <i>p</i> = 0.08). Administering a two-dose vaccination is essential to increase the levels of neutralising antibodies significantly (<i>p</i> = 0.013) in PLHIV who have received inactivated vaccines; further study is needed to make this a recommendation. The responses observed after vaccination in PLHIV were not affected by their CD4 cell counts. PLHIV showed higher levels of SARS-CoV-2 IgG and increased IL-2 and IFN-γ levels. Our study encourages SARS-CoV-2 vaccination in PLHIV regardless of its CD4 cell counts. Furthermore, the mRNA vaccine may give robust high antibody responses in PLHIV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amanah</LastName><ForeName>Amanah</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5007-816X</Identifier><AffiliationInfo><Affiliation>Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Faculty of Medicine, Swadaya Gunung Jati University, Cirebon 45132, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ariyanto</LastName><ForeName>Ibnu Agus</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0003-0576-0562</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bela</LastName><ForeName>Budiman</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9010-2427</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virology and Cancer Pathobiology Research Center, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Primanagara</LastName><ForeName>Risnandya</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0028-259X</Identifier><AffiliationInfo><Affiliation>Department of Bioinformatics, Faculty of Medicine, Swadaya Gunung Jati University, Cirebon 45132, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sudarmono</LastName><ForeName>Pratiwi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7637-2634</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta 10430, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PENG-001/UN2.RST/PPM.00.00/2023.</GrantID><Agency>University of Indonesia</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">anti-SARS-CoV-2 RBD IgG</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">mRNA vaccine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335628</ArticleId><ArticleId IdType="pmc">PMC11429386</ArticleId><ArticleId IdType="doi">10.3390/biomedicines12092115</ArticleId><ArticleId IdType="pii">biomedicines12092115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nastri B.M., Pagliano P., Zannella C., Folliero V., Masullo A., Rinaldi L., Galdiero M., Franci G. HIV and Drug-Resistant Subtypes. Microorganisms. 2023;11:221. doi: 10.3390/microorganisms11010221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11010221</ArticleId><ArticleId IdType="pmc">PMC9861097</ArticleId><ArticleId IdType="pubmed">36677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim F., Riou C., Bernstein M., Jule Z., Lustig G., van Graan S., Keeton R.S., Upton J.-L., Ganga Y., Khan K., et al. Clearance of Persistent SARS-CoV-2 Associates with Increased Neutralizing Antibodies in Advanced HIV Disease Post-ART Initiation. Nat. Commun. 2024;15:2360. doi: 10.1038/s41467-024-46673-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46673-2</ArticleId><ArticleId IdType="pmc">PMC10943233</ArticleId><ArticleId IdType="pubmed">38491050</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A., Okorie C., Marinkovic A., Patidar R., Younis K., Desai P., Hosein Z., Padda I., Mangat J., Altaf M. Comorbidity and Its Impact on Patients with COVID-19. SN Compr. Clin. Med. 2020;2:1069–1076. doi: 10.1007/s42399-020-00363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42399-020-00363-4</ArticleId><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Yuan S., Ruan S., Ning X., Li H., Liu Y., Li X. Associations between Underlying Diseases with COVID-19 and Its Symptoms among Adults: A Cross-Sectional Study. Front. Public Health. 2023;11:1210800. doi: 10.3389/fpubh.2023.1210800.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1210800</ArticleId><ArticleId IdType="pmc">PMC10298173</ArticleId><ArticleId IdType="pubmed">37383271</ArticleId></ArticleIdList></Reference><Reference><Citation>Bociąga-Jasik M., Lara M., Raczyńska A., Wizner B., Polański S., Mlicka-Kowalczyk E., Garlicki A., Sanak M. Effectiveness and Safety of SARS-CoV-2 Vaccination in HIV-Infected Patients—Real-World Study. Vaccines. 2023;11:893. doi: 10.3390/vaccines11050893.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050893</ArticleId><ArticleId IdType="pmc">PMC10222990</ArticleId><ArticleId IdType="pubmed">37242997</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance for COVID-19 and People With HIV.  [(accessed on 26 July 2024)]; Available online:  https://clinicalinfo.hiv.gov/en/guidelines/archived-guidelines/guidance-covid-19-and-people-hiv-archive.</Citation></Reference><Reference><Citation>Bessen C., Plaza-Sirvent C., Simsek A., Bhat J., Marheinecke C., Urlaub D., Bonowitz P., Busse S., Schumann S., Blanco E.V., et al. Impact of SARS-CoV-2 Vaccination on Systemic Immune Responses in People Living with HIV. Front. Immunol. 2022;13:1049070. doi: 10.3389/fimmu.2022.1049070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1049070</ArticleId><ArticleId IdType="pmc">PMC9755486</ArticleId><ArticleId IdType="pubmed">36532034</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaşın M.F., Bayraktar Z., Toygar-Deniz M., Akhan S., Özdemir M.K. COVID-19 Vaccines and COVID-19 in People Living with HIV. Infect. Dis. Clin. Microbiol. 2024;28:78–82. doi: 10.36519/idcm.2024.271.</Citation><ArticleIdList><ArticleId IdType="doi">10.36519/idcm.2024.271</ArticleId><ArticleId IdType="pmc">PMC11243773</ArticleId><ArticleId IdType="pubmed">39005697</ArticleId></ArticleIdList></Reference><Reference><Citation>Batchi-Bouyou A.L., Djontu J.C., Ingoba L.L., Mougany J.S., Mouzinga F.H., Dollon Mbama Ntabi J., Kouikani F.Y., Christ Massamba Ndala A., Diafouka-kietela S., Ampa R., et al. Neutralizing Antibody Responses Assessment after Vaccination in People Living with HIV Using a Surrogate Neutralization Assay. BMC Immunol. 2024;25:43. doi: 10.1186/s12865-024-00625-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-024-00625-z</ArticleId><ArticleId IdType="pmc">PMC11234560</ArticleId><ArticleId IdType="pubmed">38987686</ArticleId></ArticleIdList></Reference><Reference><Citation>Woldemeskel B.A., Karaba A.H., Garliss C.C., Beck E.J., Wang K.H., Laeyendecker O., Cox A.L., Blankson J.N. The BNT162b2 MRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) Clin. Infect. Dis. 2022;74:1268–1270. doi: 10.1093/cid/ciab648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab648</ArticleId><ArticleId IdType="pmc">PMC8406881</ArticleId><ArticleId IdType="pubmed">34293114</ArticleId></ArticleIdList></Reference><Reference><Citation>Heftdal L.D., Pérez-Alós L., Hasselbalch R.B., Hansen C.B., Hamm S.R., Møller D.L., Pries-Heje M., Fogh K., Gerstoft J., Grønbæk K., et al. Humoral and Cellular Immune Responses Eleven Months after the Third Dose of BNT162b2 an MRNA-Based COVID-19 Vaccine in People with HIV—A Prospective Observational Cohort Study. EBioMedicine. 2023;93:104661. doi: 10.1016/j.ebiom.2023.104661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104661</ArticleId><ArticleId IdType="pmc">PMC10272831</ArticleId><ArticleId IdType="pubmed">37331161</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y., Zhang Y., He Z., Huang H., Tian X., Wang G., Chen D., Ren Y., Jia L., Wang W., et al. Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in People Living with HIV-1: A Non-Randomized Cohort Study. EClinicalMedicine. 2022;43:101226. doi: 10.1016/j.eclinm.2021.101226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101226</ArticleId><ArticleId IdType="pmc">PMC8642727</ArticleId><ArticleId IdType="pubmed">34901799</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirtaleb M.S., Falak R., Heshmatnia J., Bakhshandeh B., Taheri R.A., Soleimanjahi H., Zolfaghari Emameh R. An Insight Overview on COVID-19 MRNA Vaccines: Advantageous, Pharmacology, Mechanism of Action, and Prospective Considerations. Int. Immunopharmacol. 2023;117:109934. doi: 10.1016/j.intimp.2023.109934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.109934</ArticleId><ArticleId IdType="pmc">PMC9968612</ArticleId><ArticleId IdType="pubmed">36867924</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebe E.C., Dejenie T.A. Protective Roles and Protective Mechanisms of Neutralizing Antibodies against SARS-CoV-2 Infection and Their Potential Clinical Implications. Front. Immunol. 2023;14:1055457. doi: 10.3389/fimmu.2023.1055457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055457</ArticleId><ArticleId IdType="pmc">PMC9892939</ArticleId><ArticleId IdType="pubmed">36742320</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Sang L., Jiang M., Yang Z., Jia N., Fu W., Xie J., Guan W., Liang W., Ni Z., et al. Longitudinal Hematologic and Immunologic Variations Associated with the Progression of COVID-19 Patients in China. J. Allergy Clin. Immunol. 2020;146:89–100. doi: 10.1016/j.jaci.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7212968</ArticleId><ArticleId IdType="pubmed">32407836</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Righi E., Konnova A., Sciammarella C., Spiteri G., Van Averbeke V., Berkell M., Hotterbeekx A., Sartor A., Mirandola M., et al. Interleukin-2-Mediated CD4 T-Cell Activation Correlates Highly with Effective Serological and T-Cell Responses to SARS-CoV-2 Vaccination in People Living with HIV. J. Med. Virol. 2024;96:e29820. doi: 10.1002/jmv.29820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29820</ArticleId><ArticleId IdType="pubmed">39056205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanbari Naeini L., Abbasi L., Karimi F., Kokabian P., Abdi Abyaneh F., Naderi D. The Important Role of Interleukin-2 in COVID-19. J. Immunol. Res. 2023;2023:7097329. doi: 10.1155/2023/7097329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/7097329</ArticleId><ArticleId IdType="pmc">PMC10465260</ArticleId><ArticleId IdType="pubmed">37649897</ArticleId></ArticleIdList></Reference><Reference><Citation>Scordio M., Frasca F., Santinelli L., Sorrentino L., Pierangeli A., Turriziani O., Mastroianni C.M., Antonelli G., Viscidi R.P., d’Ettorre G., et al. High Frequency of Neutralizing Antibodies to Type I Interferon in HIV-1 Patients Hospitalized for COVID-19. Clin. Immunol. 2022;241:109068. doi: 10.1016/j.clim.2022.109068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109068</ArticleId><ArticleId IdType="pmc">PMC9233547</ArticleId><ArticleId IdType="pubmed">35764258</ArticleId></ArticleIdList></Reference><Reference><Citation>D’ettorre G., Recchia G., Ridolfi M., Siccardi G., Pinacchio C., Innocenti G.P., Santinelli L., Frasca F., Bitossi C., Ceccarelli G., et al. Analysis of Type I IFN Response and T Cell Activation in Severe COVID-19/HIV-1 Coinfection: A Case Report. Medicine. 2020;99:e21803. doi: 10.1097/MD.0000000000021803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000021803</ArticleId><ArticleId IdType="pmc">PMC7478511</ArticleId><ArticleId IdType="pubmed">32899009</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott E.I., Wang A. Interferon Gamma Runs Interference on Persistent COVID-19. Med. 2021;2:1111–1113. doi: 10.1016/j.medj.2021.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.09.004</ArticleId><ArticleId IdType="pmc">PMC8500527</ArticleId><ArticleId IdType="pubmed">34661183</ArticleId></ArticleIdList></Reference><Reference><Citation>van Laarhoven A., Kurver L., Overheul G.J., Kooistra E.J., Abdo W.F., van Crevel R., Duivenvoorden R., Kox M., ten Oever J., Schouten J., et al. Interferon Gamma Immunotherapy in Five Critically Ill COVID-19 Patients with Impaired Cellular Immunity: A Case Series. Med. 2021;2:1163–1170.e2. doi: 10.1016/j.medj.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.09.003</ArticleId><ArticleId IdType="pmc">PMC8452508</ArticleId><ArticleId IdType="pubmed">34568856</ArticleId></ArticleIdList></Reference><Reference><Citation>Höft M.A., Burgers W.A., Riou C. The Immune Response to SARS-CoV-2 in People with HIV. Cell. Mol. Immunol. 2023;21:184–196. doi: 10.1038/s41423-023-01087-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01087-w</ArticleId><ArticleId IdType="pmc">PMC10806256</ArticleId><ArticleId IdType="pubmed">37821620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Stoesser N., Matthews P.C., Ayoubkhani D., Studley R., Bell I., Bell J.I., Newton J.N., Farrar J., Diamond I., et al. Antibody Responses to SARS-CoV-2 Vaccines in 45,965 Adults from the General Population of the United Kingdom. Nat. Microbiol. 2021;6:1140–1149. doi: 10.1038/s41564-021-00947-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00947-3</ArticleId><ArticleId IdType="pmc">PMC8294260</ArticleId><ArticleId IdType="pubmed">34290390</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa A.L., Ali K., Berman G., Zhou H., Deng W., Xu W., Lussier S., Girard B., Dutko F.J., Slobod K., et al. Safety and Durability of MRNA-1273–Induced SARS-CoV-2 Immune Responses in Adolescents: Results from the Phase 2/3 TeenCOVE Trial. EClinicalMedicine. 2024;74:102720. doi: 10.1016/j.eclinm.2024.102720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2024.102720</ArticleId><ArticleId IdType="pmc">PMC11293523</ArticleId><ArticleId IdType="pubmed">39091673</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan N., Cao H., Wang Y., Lin K., Hu J., Liu C. Comparison of Immune Responses between Inactivated and MRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice. Viruses. 2023;15:1351. doi: 10.3390/v15061351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15061351</ArticleId><ArticleId IdType="pmc">PMC10301383</ArticleId><ArticleId IdType="pubmed">37376650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D.P.C., Wong N.S., Wong B.C.K., Chan J.M.C., Lee S.S. Three-Dose Primary Series of Inactivated COVID-19 Vaccine for Persons Living with HIV, Hong Kong. Emerg. Infect. Dis. J. 2022;28:2130. doi: 10.3201/eid2810.220691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2810.220691</ArticleId><ArticleId IdType="pmc">PMC9514347</ArticleId><ArticleId IdType="pubmed">36048772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Ning J., Chen Y., Li B., Shi L., He T., Zhang F., Chen X., Zhai A., Wu C. The BBIBP-CorV Inactivated COVID-19 Vaccine Induces Robust and Persistent Humoral Responses to SARS-CoV-2 Nucleocapsid, besides Spike Protein in Healthy Adults. Front. Microbiol. 2022;13:1008420. doi: 10.3389/fmicb.2022.1008420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.1008420</ArticleId><ArticleId IdType="pmc">PMC9672472</ArticleId><ArticleId IdType="pubmed">36406456</ArticleId></ArticleIdList></Reference><Reference><Citation>Balcells M.E., Le Corre N., Durán J., Ceballos M.E., Vizcaya C., Mondaca Sebastián and Dib M., Rabagliati R., Sarmiento Mauricio and Burgos P.I., Espinoza M., Ferrés M., et al. Reduced Immune Response to Inactivated Severe Acute Respiratory Coronavirus 2 Vaccine in a Cohort of Immunocompromised in Chile. Clin. Infect. Dis. 2022;75:e594–e602. doi: 10.1093/cid/ciac167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac167</ArticleId><ArticleId IdType="pmc">PMC8903589</ArticleId><ArticleId IdType="pubmed">35255140</ArticleId></ArticleIdList></Reference><Reference><Citation>Safont G., Villar-Hernández R., Smalchuk D., Stojanovic Z., Marín A., Lacoma A., Pérez-Cano C., López-Martínez A., Molina-Moya B., Solis A.J., et al. Measurement of IFN-γ and IL-2 for the Assessment of the Cellular Immunity against SARS-CoV-2. Sci. Rep. 2024;14:1137. doi: 10.1038/s41598-024-51505-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-51505-w</ArticleId><ArticleId IdType="pmc">PMC10784529</ArticleId><ArticleId IdType="pubmed">38212416</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Li Y., Jin J., Chai Xiaoran and Ma Z., Duan J., Zhang G., Huang T., Zhang X., Zhang T., Wu H., et al. SARS-CoV-2-Specific T-Cell Responses Are Induced in People with Human Immunodeficiency Virus after Booster. Chin. Med. J. 2024 doi: 10.1097/CM9.0000000000003176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000003176</ArticleId><ArticleId IdType="pubmed">39028115</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J.M.E., Hang S.K., Hariharaputran S., Chia A., Tan N., Lee E.S., Chng E., Lim P.L., Young B.E., Lye D.C., et al. A Comparative Characterization of SARS-CoV-2-Specific T-Cells Induced by MRNA or Inactive Virus COVID-19 Vaccines. Cell Rep. Med. 2022;3:100793. doi: 10.1016/j.xcrm.2022.100793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100793</ArticleId><ArticleId IdType="pmc">PMC9534788</ArticleId><ArticleId IdType="pubmed">36257326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherneha M., Zydek I., Braß P., Korth J., Jansen S., Esser S., Karsten C.B., Meyer F., Kraiselburd I., Dittmer U., et al. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in People Living with HIV (PLWH) Vaccines. 2024;12:785. doi: 10.3390/vaccines12070785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12070785</ArticleId><ArticleId IdType="pmc">PMC11281445</ArticleId><ArticleId IdType="pubmed">39066423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mounika V.L., Kumar V.U., Dhingra S., Ravichandiran V., Pandey K., Parihar V.K., Murti K. CD4+  Count: A Variable to Be Considered to Prioritize COVID-19 Vaccination in PLHIV. Curr. Pharmacol. Rep. 2023;9:90–97. doi: 10.1007/s40495-023-00312-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40495-023-00312-4</ArticleId><ArticleId IdType="pmc">PMC9944399</ArticleId><ArticleId IdType="pubmed">36844431</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinori A., Cicalini S., Meschi S., Bordoni V., Lorenzini P., Vergori A., Lanini S., De Pascale L., Matusali G., Mariotti D., et al. Humoral and Cellular Immune Response Elicited by MRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clin. Infect. Dis. 2022;75:e552–e563. doi: 10.1093/cid/ciac238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac238</ArticleId><ArticleId IdType="pmc">PMC9047161</ArticleId><ArticleId IdType="pubmed">35366316</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfiky A.A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp): A Molecular Docking Study. Life Sci. 2020;253:117592. doi: 10.1016/j.lfs.2020.117592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117592</ArticleId><ArticleId IdType="pmc">PMC7102646</ArticleId><ArticleId IdType="pubmed">32222463</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>